OZ-001 MODE OF ACTION: A Novel Dual-Targeting Anti-Cancer Small Molecule

OZ-001 is an innovative anti-cancer small molecule designed with a dual-targeting mechanism,
uniquely inhibiting both T-type calcium channels and STAT3 signaling.
This dual approach positions OZ-001 as a highly promising single-agent therapy for cancer by:
➀ Inhibiting T-type calcium channels: Reduces intracellular calcium levels, suppresses CaMK2 phosphorylation, induces cell cycle arrest,and effectively inhibits tumor growth.
➁ Targeting the STAT3 pathway: Blocks the STAT3 signaling pathway, driving cancer cell apoptosis and enhancing anti-tumor effects.
Together, these complementary mechanisms position OZ-001 as a groundbreaking therapeutic agent with the potential to significantly slow cancer progression and induce cancer cell death.
Development Status
OZ-001 has undergone comprehensive in-vitro and in-vivo studies, including efficacy evaluations, mechanism research, and toxicity studies, across three target indications:
triple-negative breast cancer (TNBC), pancreatic cancer, and non-small cell lung cancer (NSCLC).
The IND filing for OZ-001 was successfully completed in Australia, and we are preparing to initiate clinical trials in 2025.